Find information on thousands of medical conditions and prescription drugs.

Levocetirizine

Levocetirizine (levocetirizine dihydrochloride, marketed as Xyzal in Europe) is a third generation antihistamine, developed from the second generation antihistamine cetirizine. It is more effective and has fewer side effects than the second generation drugs. more...

 Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
Labetalol
Lacrisert
Lactitol
Lactuca virosa
Lactulose
Lamictal
Lamisil
Lamivudine
Lamotrigine
Lanophyllin
Lansoprazole
Lantus
Lariam
Larotid
Lasix
Latanoprost
Lescol
Letrozole
Leucine
Leucovorin
Leukeran
Levaquin
Levetiracetam
Levitra
Levocabastine
Levocetirizine
Levodopa
Levofloxacin
Levomenol
Levomepromazine
Levonorgestrel
Levonorgestrel
Levophed
Levora
Levothyroxine sodium
Levoxyl
Levulan
Lexapro
Lexiva
Librium
Lidocaine
Lidopen
Linezolid
Liothyronine
Liothyronine Sodium
Lipidil
Lipitor
Lisinopril
Lithane
Lithobid
Lithonate
Lithostat
Lithotabs
Livostin
Lodine
Loestrin
Lomotil
Loperamide
Lopressor
Loracarbef
Loratadine
Loratadine
Lorazepam
Lortab
Losartan
Lotensin
Lotrel
Lotronex
Lotusate
Lovastatin
Lovenox
Loxapine
LSD
Ludiomil
Lufenuron
Lupron
Lutropin alfa
Luvox
Luxiq
Theophylline
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

In some studies it has been shown to be non-sedative unlike many previous antihistamines. It has been reported that it can solve sleeping problems for some people.

Chemically, levocetirizine is the active enantiomer of cetirizine.

Xyzal is available in 5 mg tablets and is made by Belgian pharmaceutical company UCB. Xyzal was first launched in 2001. The patent on levocetirizine will expire in 2013.

Read more at Wikipedia.org
• [List your site here Free!]

Chronic urticaria: clinical aspects and focus on a new antihistamine, levocetirizine.(ARTICLES) : An article from: Journal of Drugs in Dermatology $5.95

Chronic urticaria: clinical aspects and focus on a new antihistamine, levocetirizine
Abstract Chronic urticaria (CU) involves release of histamine from mast cells and/or basophils, which in turn promotes the classic inflammatory cascade.
From Journal of Drugs in Dermatology, 11/1/04 by A. Kapp
The new antihistamines—desloratadine and levocetirizine: a review
Introduction Antihistamines are among the most commonly used medications by allergists and dermatologists worldwide. They are used to treat indications ...
From Journal of Drugs in Dermatology, 12/1/02 by Noah Scheinfeld
UCB confirms positive outlook for 2005
UCB confirms its previous guidance that net income after tax for the year to December 31, 2005 will be at least EUR260 million (not including the ...
From Market Wire, 12/12/05
Sepracor Announces Second Quarter 2005 Operating Results
MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced its consolidated financial results for the second quarter of 2005. For the three months ended June 30, 2005, Sepracor's consolidat
From Business Wire, 7/19/05

Home Contact Resources Exchange Links ebay